• Home
  • Pemigatinib 4.5mg
  • Pemigatinib 4.5mg

Pemigatinib 4.5mg

52112

Pemigatinib is used for adults with previously treated cholangiocarcinoma that cannot be removed by surgery or has spread and has an FGFR2 fusion or rearrangement.

It is also used for myeloid or lymphoid cancers with an FGFR1 rearrangement when the disease has come back or cannot be controlled with standard treatment.

Usual adult dose range: 4.5mg to 13.5mg once daily for 14 days followed by 7 days off; the usual starting dose is 13.5mg once daily on that schedule.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.